in Younger and Older African Americans and Whites

Slides:



Advertisements
Similar presentations
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Advertisements

Alzheimer’s Disease Edwin Onattu P. 3.
Supported by grants from: National Human Genome Research Institute (ELSI) HG/AG (The REVEAL Study); National Institute on Aging AG (The MIRAGE.
Healthy Purdue Stacey L. Mobley, PhD, RD, CNSD Assistant Professor Department of Foods and Nutrition A Platform for Research in Disease Prevention and.
AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.
Dementia and Aging Steven Huege, M.D Assistant Professor of Clinical Psychiatry Perelman School of Medicine at the University of Pennsylvania.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
CSF sulfatide is decreased in individuals with incipient dementia Xianlin Han, PhD, Anne M. Fagan, PhD, Hua Cheng, MS, John C. Morris, MD, Chengjie Xiong,
Epidemiology of Dementia in Canada: Information from the Canadian Study of Health and Aging.
Healthy Mind, Healthy Sight.. u Dr. Guy Eakin, BrightFocus Foundation u Dr. Elia Duh, Johns Hopkins University u Dr. Seth Margolis, Johns Hopkins University.
Knowledge, Cancer Fatalism and Spirituality as Predictors of Breast Cancer Screening Practices for African American and Caucasian Women Staci T. Anderson,
Alzheimer In Hispanics In Massachusetts Over the General Population BY: Emanuelly Ribeiro and Thy Pham 1.
Decision presented by the committee board members: Nicholas Mann & Katelyn Strasser FUTURE FUNDING FOR ALZHEIMER’S DISEASE October 14, 2014 MPH 543 Leadership.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
ALZHEIMER’S PART 2. AD VIDEO
Mild Cognitive Impairment
Progress Report on Alzheimer’s Disease Taking the Next Steps NIA NIH.
INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
Re-Screening of CT Positive Clients in Region X IPP, Goldenkranz S., 1 Fine D. 1 1 Center for Health Training 2010 CDC STD Prevention Meeting,
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.
The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
ACT on Alzheimer’s Disease Curriculum Module II: Demographics.
Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.
Symptom Distress During Breast Cancer Chemotherapy Does Race Matter? Margaret Quinn Rosenzweig, PhD, FNP-BC,AOCNP Associate Professor University of Pittsburgh.
Module 3: Alzheimer’s Disease – What is the Role of Public Health? A Public Health Approach to Alzheimer’s and Other Dementias.
UC Davis Alzheimer’s Disease Center The Residual Approach to Measuring Cognitive Reserve in Aging and Dementia Bruce Reed & Dan Mungas University of California,
Laura Baker, PhD Wake Forest School of Medicine.
Need For Action. Blood glucose levels are higher than normal but not yet diabetes ** 1 in 3 American adults (79 million) have prediabetes Occurs before.
A PUBLIC HEALTH APPROACH TO ALZHEIMER’S AND OTHER DEMENTIAS ALZHEIMER’S DISEASE – WHAT IS THE ROLE OF PUBLIC HEALTH?
Frailty & Falls in Community Dwelling Elderly Cancer Survivors Sandra Spoelstra, PhD, MSN, RN 1 ; Barbara Given, PhD, RN, FAAN 1 ; Charles Given, PhD 3.
Laura Baker, PhD Internal Medicine, Neurology, & Public Health Sciences Wake Forest School of Medicine Winston-Salem, NC USA.
WISCONSIN ALZHEIMER’S DISEASE RESEARCH CENTER
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
José L Molinuevo, Craig Ritchie, Miia Kivipelto
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Whitney Wharton, PhD Cognitive Neuroscientist Assistant Professor Department of Neurology Emory University.
Falls and Fractures in Community Dwelling Elderly Cancer Survivors
COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE   Mirjana Babić Leko1, Matea Nikolac Perković2,
Presentation for the SCTR Scientific Retreat on Aging Related Research
What will it take to develop an effective Alzheimer’s drug?
Robert H. Keefe, PhD, ACSW Sandra D. Lane, PhD, MPH
Module 4: Colorectal Cancer
Imaging AD Progression Amyloid Imaging Agents.
Peripheral Arterial Disease
Cognitive Disorders and Aging
From the Indianapolis – Ibadan Dementia Research Project.
COGNITIVE DECLINE IN THE WORKPLACE
Progress Report on Alzheimer’s Disease
Early Dementia Distinguishing AD From MCI
Blood-Based Biomarkers in the QC Program?
José L Molinuevo, Craig Ritchie, Miia Kivipelto
Adam P. Spira, Ph.D. Associate Professor, Department of Mental Health
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Argentina Arg-ADNI Ezequiel Surace, PhD.
Boston Naming Test predicts deterioration of cerebrospinal fluid biomarkers in pre-symptomatic Alzheimer’s disease Charleen Wilder, MA, Kristina Moncrieffe,
UC Davis Data Summary Psychometrics 2018.
M Javanbakht, S Guerry, LV Smith, P Kerndt
Chapter 25 The Elderly.
Columbia University Medical Center
Overview of Health Disparities in Aging And Alzheimer’s Disease and Related Dementias Carolina Center on Alzheimer’s Disease and Minority Research (CCARMR)
Alzheimer's Prevention Research and
Ongoing Research With Vascular Risk Factors and the RAS in Individuals at Risk for AD Whitney Wharton, PhD Assistant Professor,
ACT on Alzheimer’s Disease Curriculum
Association between cognitive impairment and cerebrovascular disease
Presentation transcript:

in Younger and Older African Americans and Whites Different CSF Total Tau and Phosphorylated Tau, but not Aβ, in Younger and Older African Americans and Whites Whitney Wharton, PhD Associate Professor, Nursing & Neurology Emory University

Funding, Disclosures No Disclosures Funding NIA K01, R01, Admin Supp to Address Health Disparities NINR Alzheimer’s Association PTC VA Emory ADRC and School of Nursing

Early Detection MCI Mild AD Moderate AD Severe AD Increasing Age Normal Cognition MCI Worse Cognitive Abilities  better Mild AD Moderate AD Start Treatment HERE Severe AD 95 Years Increasing Age

Shifting the curve What factors can we identify that…. Are linked to cognitive decline Are linked to AD pathology (plaques and tangles) Occur during midlife Treatable / reversible

Who is most at risk for AD? African Americans Women Middle Age Increased Vascular risk Family History Caregivers To Help the Most People Possible, We Must Target Those Most at Risk!!

The meta-analysis showed that the AD rate for AAs was 64% higher than for Whites (RR = 1.64 (95% CI 1.35-2.00)), with no evidence of heterogeneity. We estimated the current US AD prevalence for ages 65–90 to be 5.5% for Whites, and 8.6% for AAs (prevalence ratio 1.56) African Americans have increased incidence AND prevalence

Prevention Study for High Risk Individuals: ASCEND Observational, NIA funded N=80, 2 yrs, annual visits, 45-65yrs, parental history of AD Determine the extent to which change in peripheral vascular function may influence 1) Aβ, tau in CSF 2) CSF and blood inflammation 3) cognition EndoPAT, FMD, PWV, plasma RAS and ambulatory blood pressure CSF, MRI, blood, cognitive testing, inflammatory markers, extensive Qs (sleep, exercise, nutrition, stress, discrimination, sexual and reproductive history)

Demographics and Clinical

AD Biomarkers in CSF

Race differences in CSF p-tau and t-tau, but not Aβ Race modified the relationship between t-tau & IL-9 (p=0.018), and p-tau and IL-9 (p<0.001)

Take Away This is the 3rd study to show reduced p and t tau, but not Aβ, in African Americans vs Whites First study to show changes in middle age, healthy cohort 3 studies, different labs and platforms